WO2003002530A2 - Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase - Google Patents
Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase Download PDFInfo
- Publication number
- WO2003002530A2 WO2003002530A2 PCT/US2002/020466 US0220466W WO03002530A2 WO 2003002530 A2 WO2003002530 A2 WO 2003002530A2 US 0220466 W US0220466 W US 0220466W WO 03002530 A2 WO03002530 A2 WO 03002530A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- disorders
- alkyl
- amino
- dpp
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
- C07D207/48—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/04—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D277/06—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
Definitions
- the present invention relates to compounds inhibiting dipeptidyl peptidases
- DPP-II II
- IV IV
- Dipeptidyl peptidase IV is a post-proline/alanine cleaving serine
- DPP-IV is thought to regulate the activity of multiple physiogically important
- peptides including, but not limited to, GLP1 , GIP, GLP2, GRP, vasoactive intestinal
- PACAP38 prolactin, chorionic gonadotropin, aprotinin, corticotropin-like intermediate
- LD78beta(3-70) RANTES, eotaxin procolipase, enterostatin, vasostatin 1, endomorphin,
- DPP-IV DPP-IV is believed to be involved in a variety of metabolic
- gastrointestinal, viral, and inflammatory diseases including, but not limited to,
- diabetes obesity, hyperlipidemia, dermatological or mucous membrane disorders,
- Iipodystrophy and tissue damage, psychosomatic, depressive, and neuropsychiatric
- cytokine-mediated murine abortions examples include DPP-IV, also known as
- T-cells mediates T-cell activation and HIV infection (Ohtsuki et al., 2000).
- DPP-IV/CD26 are preferentially infected and depleted in HIV-infected
- DPP-IV is thought to regulate metabolism by cleaving the penultimate proline/alanine
- GLP GLP
- NPY neuropeptide Y
- GLPs help metabolize glucose and, thus, regulation of GLPs
- Diabetes for example type 2 (also called noninsulin-dependent diabetes mellitus).
- Type 2 diabetes is the more common
- Insulin attaches to
- glucose does not get inside, a condition known as insulin
- GLP-1 overcome insulin resistance.
- GLP-1 enhances insulin secretion.
- GLP-1 correlates to a regulation of insulin secretion. Moreover, GLP-1 decreases hepatic glucose production, gastric emptying, and food intake (Deacon et al., 1995).
- GLP-2 maintains the integrity of the intestinal mucosal epithelium via effects
- DPP-IV inhibitors preserve GLP-1 function for a longer time (Balka, 1999).
- DPP-IV inhibitors may promote satiety, weight loss, and the antidiabetic effects
- Diabetologia 42: 1324-1331 Both subcutaneously and intravenously administered
- GLP-1 is rapidly degraded from the NH 2 -terminus in type II diabetic patients and in
- DPP-IV inhibitors preserve GLP-2 for longer periods of time and,
- DPP-IV is the predominate protease regulating GLP turnover, similar
- proteases include, but are not limited to, dipeptidyl peptidase-ll (DPP-II), dipeptidyl
- fibroblast activating protein alpha seprase
- prolyl tripeptidyl peptidase prolyl
- oligopeptidase endoproteinase Pro-C
- attractin soluble dipeptidyl-aminopeptidase
- acylaminoacyl-peptidase N-acylpeptide hydrolase; fMet aminopeptidase
- lysosomal Pro-X carboxypeptidase angiotensinase C, prolyl carboxypeptidase.
- Proline-cleaving metallopeptidases that may share similar substrate or inhibitor specificity to DPP-IV include membrane Pro-X carboxypeptidase (carboxypeptidase P),
- elastase metaloelastase; matrix metalloproteinase 12; MMP-12], Matrilysin (matrix
- metallopeptidases other non-mammalian proteases may share similar substrate or
- proteases include prolyl aminopeptidase (prolyl iminopeptidase), lgA1 -specific serine
- aminopeptidase A (STE13) [Saccharomyces cerevisiae), dipeptidyl aminopeptidase B
- non-mammalian proline-cleaving metallopeptidases include
- penicillolysin fungal acid metalloendopeptidase
- Dipeptidyl peptidase II (DPP II) is a serine protease localized to lysosomes in
- DPP-II has significant sequence
- the present invention includes novel DPP-II and/or DPP-IV inhibitors, as well as
- diabetes including, but not limited to, diabetes, obesity, hyperlipidemia, dermatological or
- neuropsychiatric disease such as anxiety, depression, insomnia, schizophrenia, epilepsy,
- the present invention includes compounds of formula (I):
- X is -S(0)b- or -CH2-; b is 0-2; R 1 and R 2 each are either H; alkyl; optionally substituted
- aryl or heteroaryl or combine to form a 3 to 14 membered ring sytem, optionally
- R 1 and R 2 are optionally substitued aryl or heteroaryl, then R 3 is
- R 4 is R 5 when Y is S, 0, alkylene, alkenylene, alkynylene, or a bond, where R 5 is
- R 4 is R 6 when Y
- R 6 is alkyl, aryl, cycloalkyl, heteroaryl, amino, alkylamino,
- arylamino arylamino, heteroarylamino, or cycloalkylamino.
- R 1 and R 2 are each alkyl and R 3 is
- each alkyl is G-Cs alkyl. More preferably, each of alkyl is methyl. lii a particular compound included within the present invention X is -S(0)b-, b
- R 5 is optionally substituted aryl.
- R 5 is phenyl substituted with alkoxy.
- X is -CH2-, n is
- m is 1
- Y is -S(0) P -
- p is 1
- R 4 is R 5
- R 5 is optionally substituted aryl.
- R 5 is phenyl substituted with alkoxy.
- X is -CH2-, n is
- R 6 is optionally substituted aryl.
- X is S(0)b
- b is
- n 0, m is 1 , Y is S(0) P , p is 2, R 4 is R 6 , and R 6 is optionally substituted aryl.
- the depicted NH2 group is cis to the
- depicted nitrile warhead preferably the depicted NH2 group is
- Particularly preferred compounds of the present invention include:
- the present invention also includes pharmaceutical formulation comprising a
- pharmaceutical formulation further includes a pharmaceutically acceptable carrier.
- the present invention also includes a method of inhibiting a post
- proline/analine cleaving protease comprising administering a compound of the
- the dipeptidyl peptidase is DPP-II. In another aspect
- the dipeptidyl peptidase is DPP-IV.
- the present invention also includes a method for the treatment or prophylaxis
- diabetes preferably Type II diabetes.
- the present invention also includes the use of a compound of the present
- proline/analine cleaving protease is a serine protease. More preferably, the serine protease is a dipeptidyl peptidase. In one aspect preferably the dipeptidyl peptidase is
- DPP-II In another aspect preferably the dipeptidyl peptidase is DPP-IV.
- the present invention also includes the use of a compound of the present
- the present invention also includes a compound the present invention as
- present invention inlcudes a compound the present invention as herein described for
- diabetes obesity, hyperlipidemia, dermatological or mucous membrane disorders,
- alkyl refers to a straight or branched chain saturated aliphatic
- hydrocarbon that may be optionally substituted, with multiple degrees of substitution
- alkyl examples include, but are not limited to methyl, ethyl, n-
- propyl isopropyl, n-butyl, t-butyl, n-pentyl, isobutyl, and the like.
- alkylene refers to a divalent straight or branched chain aliphatic
- hydrocarbon radical that may be optionally substituted, with multiple degrees of
- alkylene includes, without limitation,
- alkenyl refers to a straight or branched chain aliphatic
- hydrocarbon containing one or more carbon-to-carbon double bonds that may be
- alkenylene refers to a divalent straight or branched
- alkenylene includes, without limitation, vinylene,
- alkynyl refers to a straight or branched aliphatic
- hydrocarbon containing one or more triple bond which may optionally be substituted, with multuiple degrees of substitution being allowed.
- alkynyl as used
- alkynylene refers to a divalent straight or branched
- substituted benzene ring system such as phenyl.
- substituted benzene ring system such as phenyl.
- the term encompasses fused systems
- alkylene linker such as C ⁇ -Cs alkylene
- aryl groups include, but are not limited to
- heteroaryl refers to a monocyclic aromatic ring system, or to a
- heteroaryl rings contain one or more nitrogen, sulfur, and/or oxygen atoms, where N-
- rings may be optionally substituted, with multiple degrees of substitution being
- the term includes ring(s) optionally substituted, with multiple degrees of
- substitution being allowed, and also includes an optional alkylene linker, such as G-Ce
- heteroaryl groups used herein include furan, thiophene, pyrrole, imidazole, pyrazole,
- cycloalkyl refers to a mono- or bi-cyclic
- hydrocarbon ring system which may be further substituted with multiple degrees of
- cycloalkyl examples include, but are
- cycloalkyl includes bridged or fused ring systems, as well, such as
- cycloalkyl/aryl fused systems where, for example, a cycloalkyl, such as
- cyclohexyl is fused with an aromatic ring, such as a benzene ring, to form groups such
- heterocyclic or the term “heterocyclyl” refers to a
- heterocyclic ring preferably three to twelve-membered, that is either saturated or has
- heterocyclic rings contain one or more
- heteroatom such as nitrogen, sulfur, and/or oxygen atoms, where N-oxides, sulfur
- heterocyclic groups optionally may be substituted, with multiple degrees of
- substitution being allowed, and also includes an optional alkylene linker, such as G-Cs
- cycloalkyl ring(s) examples include, but are not limited to,
- alkoxy refers to the group -ORa, where Ra is alkyl as
- amino refers to the group -NH2.
- alkylamino refers to the group -N(Ra)2, where one Ra
- Ra is alkyl and the other Ra independently is H or alkyl, as herein defined.
- cycloalkylamino refers to the group -N(Ra)2, where
- Ra is cycloalkyl and the other Ra independently is H or cycloalkyl, as herein
- heteroarylamino refers to the group -N(Ra) 2 , where
- one Ra is heteroaryl and the other Ra independently is H or heteroaryl, as herein defined.
- acyl alkyl; alkenyl; alkynyl; alkylsulfonyl; alkoxy; cyano; halogen; haloalkyl; hydroxy;
- aryl which may be further substituted with acyl, alkoxy, alkyl, alkenyl, alkynyl,
- alkylsulfonyl cyano, halogen, haloalkyl, hydroxy, or nitro; heteroaryl, which may be
- aryloxy which may be further substituted with acyl, alkoxy, alkyl, alkenyl,
- alkynyl alkylsulfonyl, cyano, halogen, haloalkyl, hydroxy, or nitro; heteroaryloxy,
- alkylsulfonyl cyano, halogen, haloalkyl, hydroxy, or nitro; -R'OR'R 4 ; or -NR 4 R 5 ;
- heteroaryl alkylsulfonyl, arylsulfonyl, or heteroarylsulfonyl, where each occurrence of
- Such aryl or heteroaryl may be substituted with one or more acyl, alkoxy, alkyl,
- the compounds of the present invention may have the ability to crystallize in
- polymorphism a characteristic known as polymorphism. All polymorphic forms
- Polymorphs are within the scope of the present invention. Polymorphism generally
- present invention includes pure stereoisomers as well as mixtures of stereoisomers
- the present invention covers the individual isomers of the
- the present invention includes salts, solvates, and
- Salts include addition salts, metal salts, or optionally alkylated ammonium salts.
- salts examples include hydrochloric, hydrobromic, hydroiodic, phosphoric,
- salts include acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate,
- borate bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate,
- phosphate/diphosphate polygalacturonate
- potassium salicylate
- sodium sodium, stearate
- solvate refers to a complex of variable stoichiometry
- solvents include, but are not limited to
- the solvent used is a
- solvents include water, ethanol, and acetic acid.
- an ester or an amide which upon administration to a mammal is capable of
- the present invention further includes a pharmaceutical formulation
- insulin one or more of the following agents: insulin, ⁇ -glucosidase inhibitors, biguanides,
- insulin secretagogue or insulin sensitizers.
- insulin secretagogue or insulin sensitizers.
- insulin secretagogue or insulin sensitizers.
- insulin secretagogue or insulin sensitizers.
- insulin secretagogue or insulin sensitizers.
- insulin secretagogue or insulin sensitizers.
- insulin secretagogue or insulin sensitizers.
- insulin secretagogue or insulin sensitizers.
- inhibitors include acarbose, emiglitate, miglitol, and voglibose.
- biguanides include metformin, buformin, and phenformin.
- metformin metformin
- buformin metformin
- phenformin phenformin
- insulin secretagogues include sulphonylureas.
- sensitizers include peroxisome proliferator activated receptor (PPAR) ligands, such as
- PPAR- ⁇ agonists for example ActosTM and AvandiaTM.
- Formulations of the present invention include those especially formulated for
- capsules, and caplets may contain conventional excipients such as binding agents, fillers, lubricants,
- binding agents are disintegrants, and/or wetting agents.
- binding agents include disintegrants, and/or wetting agents.
- syrup examples include syrup, acacia, gelatin, sorbitol, tragacanth, mucilage of starch, or
- PVP polyvinylpyrrolidone
- lactose sugar, microcrystalline cellulose, maize-starch, calcium phosphate or sorbitol.
- Non-limiting examples of lubricants include, for example, magnesium sterate, stearic
- the compounds of the present invention may be incorporated
- oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions,
- compositions containing these compounds may be
- Liquid preparations may contain conventional additives.
- Non-limiting examples are examples of
- suspending agents such as sorbitol syrup, methyl cellulose,
- glucose/sugar syrup gelatin, hydroxyethylcellulose, carboxymethyl cellulose,
- non-aqueous vehicles such as lecithin, sorbitan mono-oleate or acacia; non-aqueous vehicles (which may
- edible oils such as almond oil, fractionated coconut oil, oily esters, propylene
- glycol or ethyl alcohol my be included.
- preservatives such as methyl or propyl
- p-hydroxybenzoates or sorbic acid may be incorporated into the preparation.
- preparations may also be formulated as suppositories, for example, containing
- formulations of the present invention may be formulated for any convenient suppository bases such as cocoa butter or other glycerides. Additionally, formulations of the present invention may be formulated for any convenient suppository bases such as cocoa butter or other glycerides. Additionally, formulations of the present invention may be formulated for any convenient suppository bases such as cocoa butter or other glycerides. Additionally, formulations of the present invention may be formulated for any convenient suppository bases such as cocoa butter or other glycerides. Additionally, formulations of the present invention may be formulated for any suitable suppository bases such as cocoa butter or other glycerides. Additionally, formulations of the present invention may be formulated for any suitable suppository bases such as cocoa butter or other glycerides. Additionally, formulations of the present invention may be formulated for any suitable suppository bases such as cocoa butter or other glycerides. Additionally, formulations of the present invention may be formulated for any suitable suppository bases such as cocoa butter
- injection may take such forms as suspensions, solutions, or emulsions in oily or
- aqueous vehicles may contain formulatory agents such as suspending, stabilizing
- the active ingredient may be in powder form
- a suitable vehicle for example, sterile, pyrogen-free water, before use.
- formulations according to the invention may also be formulated as a
- depot preparation Such long acting formulations may be administered by:
- the compounds of the invention may be formulated with
- suitable polymeric or hydrophobic materials such as an emulsion in an acceptable oil
- compositions may be presented in unit dose forms containing a
- Such a unit may contain
- Such amounts include the formulation containing about 0.1 to
- a predetermined dose such as a daily dose, or an appropriate fraction
- Such pharmaceutical formulations may be prepared
- the term "effective amount” means that amount of a drug or
- terapéuticaally effective amount means any one of
- DPP-IV for purposes of treatment or prophylaxis of a variety of metabolic
- gastrointestinal, viral, and inflammatory diseases including, but not limited to,
- diabetes obesity, hyperlipidemia, dermatological or mucous membrane disorders,
- Iipodystrophy and tissue damage, HIV infection, allergies, inflammation, arthritis,
- transplant rejection high blood pressure, congestive heart failure, tumors, and stress-induced
- induced abortions for example cytokine-mediated murine abortions. No toxicological effects are indicated/expected when a compound of the
- present invention is administered in the above mentioned dosage range.
- IUPAC names are included to further identify particular compounds of the present invention.
- the IUPAC names stated herein should in no way limit the scope of the present invention.
- one embodiment of the compounds of the present invention can be prepared by reacting a compound of
- aminocarboxylates both designated herein generally as aminocarboxylates, under standard coupling conditions, for example, with HATU, DMF, Hunigs base.
- amino carboxylate where the amino carboxylate is suitably protected, for example on the ⁇ - nitrogen, with an appropriate protecting group such as, for example, a t-butyl carboxy protecting group.
- a compound of formula II may be reacted with an
- amino activated carboxylate such as, for example, N-hydroxysuccinimide ester or acid
- reaction mixture was stirred for 30 minutes at 0°C and then for 14 hours
- reaction mixture was stirred at RT for 5 minutes. A white solid precipitated during
- reaction mixture was stirred at RT for 5 minutes. A white solid precipitated during
- triisopropylbenzenesulfonyl azide (trisyl azide) (1.84 g, 5.94 mmol) in THF (10 mL, anhydrous) was added in one portion. After 3 minutes acetic acid was added (1.31 g,
- H-Ala-Pro-pNA «HCI was purchased from BACHEM Bioscience Inc. (product no.
- Gly-Pro-AMC was purchased from Enzyme System Products (product no.
- the purified human DPP-IV The material was isolated from human prostasomes using
- DPP-IV (20 ng/mL) was
- test compounds mixed in microtiter plates with test compounds, substrate and assay buffer to yield
- the enzymatic activity was determined by estimating
- Vmax was the best fit estimate of the maximal enzymatic activity.
- Ki values were calculated from ICso values using equation
- the intermediate plate contained 5.3 ⁇ L of test compound in 2-fold serial
- assay were 100 nM enzyme and 1000 ⁇ M substrate in 100 mM NaOAc, pH 5.5, 2.5%
- Vmax was the best fit estimate of the maximal enzymatic activity.
- Ki values were calculated from ICso values using equation
- Certain compounds of the present invention showed activity for DPP-II, for
- the filters set at 360 nm excitation and 460 nm emission.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pregnancy & Childbirth (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Child & Adolescent Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Gynecology & Obstetrics (AREA)
Abstract
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60223920T DE60223920T2 (de) | 2001-06-27 | 2002-06-26 | Pyrrolidine als dipeptidyl-peptidase-inhibitoren |
AU2002316437A AU2002316437A1 (en) | 2001-06-27 | 2002-06-26 | Pyrrolidines as dipeptidyl peptidase inhibitors |
JP2003508713A JP4300108B2 (ja) | 2001-06-27 | 2002-06-26 | ジペプチジルペプチダーゼ阻害剤としてのピロリジン類 |
US10/481,288 US7196201B2 (en) | 2001-06-27 | 2002-06-26 | Pyrrolidines as dipeptidyl peptidase inhibitors |
EP02746739A EP1399420B1 (fr) | 2001-06-27 | 2002-06-26 | Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30133301P | 2001-06-27 | 2001-06-27 | |
US60/301,333 | 2001-06-27 | ||
US38701102P | 2002-06-06 | 2002-06-06 | |
US60/387,011 | 2002-06-06 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003002530A2 true WO2003002530A2 (fr) | 2003-01-09 |
WO2003002530A3 WO2003002530A3 (fr) | 2003-04-03 |
Family
ID=26972304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/020466 WO2003002530A2 (fr) | 2001-06-27 | 2002-06-26 | Pyrrolidines servant d'inhibiteurs de dipeptidyl peptidase |
Country Status (8)
Country | Link |
---|---|
US (1) | US7196201B2 (fr) |
EP (1) | EP1399420B1 (fr) |
JP (1) | JP4300108B2 (fr) |
AT (1) | ATE380175T1 (fr) |
AU (1) | AU2002316437A1 (fr) |
DE (1) | DE60223920T2 (fr) |
ES (1) | ES2296962T3 (fr) |
WO (1) | WO2003002530A2 (fr) |
Cited By (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004002986A2 (fr) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Nouveaux dérivés de benzimidazole |
WO2004050022A2 (fr) * | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Derives de phenylalanine utilises comme inhibiteurs de la dipeptidylpeptisase pour le traitement ou la prevention de diabetes |
WO2004098625A2 (fr) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Utilisation d'effecteurs de glutaminyl- et de glutamate-cyclases |
WO2004098591A2 (fr) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibiteurs de glutaminyl-cyclase |
WO2004104215A2 (fr) * | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Approches diagnostiques et therapeutiques des maladies associees a la dipeptidylpeptidase 7 (dpp7) |
WO2005028438A1 (fr) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de piperidine |
WO2005033099A2 (fr) * | 2003-10-03 | 2005-04-14 | Glenmark Pharmaceuticals Ltd. | Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant |
WO2005049027A2 (fr) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinaisons utiles au traitement de troubles neuronaux |
WO2005049022A2 (fr) * | 2003-11-17 | 2005-06-02 | Novartis Ag | Utilisation de composes organiques |
WO2005075436A2 (fr) | 2004-02-05 | 2005-08-18 | Probiodrug Ag | Nouveaux inhibiteurs de la glutaminyl-cyclase |
WO2005097759A1 (fr) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Utilisation de diaryltriazoles comme inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase-1 |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
WO2006017542A1 (fr) | 2004-08-06 | 2006-02-16 | Merck & Co., Inc. | Composés de sulfonyle comme inhibiteurs de la 11-béta-hydroxystéroide déshydrogénase-1 |
US7026316B2 (en) | 2001-03-27 | 2006-04-11 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2006129826A1 (fr) | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de piperidine |
WO2007018248A1 (fr) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Composé de pyridone |
WO2007024004A1 (fr) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Dérivé phénylpyridone |
WO2007029847A1 (fr) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Dérivé de pyridone substitué aromatique bicylique |
WO2007041052A2 (fr) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4 |
WO2007049798A1 (fr) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de benzoxathiine |
WO2007055418A1 (fr) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | Derive spiro aza-substitue |
EP1801098A1 (fr) | 2005-12-16 | 2007-06-27 | Merck Sante | Dérivés de 2-Adamantylurea comme inhibiteurs de 11B-HSD1 |
WO2007072083A1 (fr) | 2005-12-23 | 2007-06-28 | Prosidion Limited | Traitement du diabete de type 2 par combinaison d'un inhibiteur de dpiv a de la metformine ou de la thiazolidinedione |
WO2007120702A2 (fr) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur de gpr119 dans des procédés d'augmentation de la masse osseuse et de traitement de l'ostéoporose et autres états se caractérisant par une masse osseuse faible, et thérapie de combinaison associée |
WO2008038692A1 (fr) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
WO2008055945A1 (fr) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies |
WO2008065141A1 (fr) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Nouveaux inhibiteurs de glutaminylcyclase |
WO2008074384A1 (fr) | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Dérivés de 2-adamantyle-butyramide en tant qu'inhibiteurs sélectifs de 11βêta-hsd1 |
WO2008120653A1 (fr) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Dérivé d'indoledione |
WO2008120813A1 (fr) | 2007-04-03 | 2008-10-09 | Mitsubishi Tanabe Pharma Corporation | Utilisation combinée de composé inhibiteur de dipeptidylpeptidase iv, et d'adoucisseur |
WO2008137105A1 (fr) | 2007-05-07 | 2008-11-13 | Merck & Co., Inc. | Procédé de traitement à l'aide de composés aromatiques fusionnés ayant une activité anti-diabétique |
US7560455B2 (en) | 2003-05-14 | 2009-07-14 | Merck & Co., Inc. | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
EP2088154A1 (fr) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Procédés et compositions pour le traitement de troubles gastro-intestinaux |
WO2009110510A1 (fr) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | Dérivé d'alkylaminopyridine |
WO2009119726A1 (fr) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | Dérivé de diarylméthylamide à activité antagoniste sur un récepteur d'hormone concentrant la mélanine |
EP2110374A1 (fr) | 2008-04-18 | 2009-10-21 | Merck Sante | Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR |
EP2116235A1 (fr) | 2005-01-10 | 2009-11-11 | Arena Pharmaceuticals, Inc. | Thérapie combinée pour le traitement des diabètes et des conditions associées, et pour le traitement des conditions améliorées par l'augmentation du niveau de sang GLP-1 |
WO2009154132A1 (fr) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | Dérivé de spirodiamine-diarylcétoxime |
WO2010013595A1 (fr) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons)–(6 chaînons) |
WO2010047982A1 (fr) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques |
WO2010051236A1 (fr) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Antagonistes d'isonicotinamide des récepteurs de l'orexine |
WO2010051206A1 (fr) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques |
WO2010056717A1 (fr) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Amines bicycliques substituées pour le traitement du diabète |
US7728146B2 (en) | 2006-04-12 | 2010-06-01 | Probiodrug Ag | Enzyme inhibitors |
EP2191824A1 (fr) | 2005-06-10 | 2010-06-02 | Novartis AG | Formulation de 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile à libération modifiée |
EP2206496A1 (fr) | 2003-05-05 | 2010-07-14 | Probiodrug AG | Utilisation médicale d'inhibiteurs de glutaminyl- et de glutamate cyclases |
US7842707B2 (en) | 2004-07-23 | 2010-11-30 | Nuada, Llc | Peptidase inhibitors |
WO2011005929A1 (fr) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Dérivé de pipéridine et son utilisation pour le traitement du diabète et de l'obésité |
WO2011011508A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés doxazépine benzofusionnés en tant quinhibiteurs de la coenzyme-stéaroyle a delta-9 désaturase |
WO2011011506A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
EP2289498A1 (fr) | 2003-10-15 | 2011-03-02 | Probiodrug AG | Utilisation des inhibiteurs de la glutaminyl cyclase |
WO2011029920A1 (fr) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase |
EP2305352A1 (fr) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques |
WO2011058193A1 (fr) | 2009-11-16 | 2011-05-19 | Mellitech | Dérivés de [1,5]-diazocine |
WO2011069038A2 (fr) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonistes de la guanylate cyclase utiles dans le traitement de l'hypercholestérolémie, de l'athérosclérose, d'une coronaropathie, des calculs biliaires, de l'obésité et d'autres maladies cardiovasculaires |
US7960384B2 (en) | 2006-03-28 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2011106273A1 (fr) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques |
WO2011107530A2 (fr) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Nouveaux inhibiteurs |
WO2011110613A1 (fr) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011127051A1 (fr) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur de gpr119 et traitement de troubles associés |
WO2011131748A2 (fr) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Nouveaux inhibiteurs |
US8084605B2 (en) | 2006-11-29 | 2011-12-27 | Kelly Ron C | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
WO2012027331A1 (fr) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés |
WO2012040279A1 (fr) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés |
US8222411B2 (en) | 2005-09-16 | 2012-07-17 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2012116145A1 (fr) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques |
WO2012118972A2 (fr) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Procédé de préparation d'agonistes du guanylate cyclase c |
WO2012123563A1 (fr) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase |
WO2012135570A1 (fr) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés |
WO2012145604A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012145603A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012145361A1 (fr) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012170702A1 (fr) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci |
WO2013055910A1 (fr) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés |
WO2013059222A1 (fr) | 2011-10-19 | 2013-04-25 | Merck Sharp & Dohme Corp. | Antagonistes des récepteurs de l'orexine à base de 2-pyrydyloxy-4-nitrile |
WO2013138352A1 (fr) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation |
WO2014022528A1 (fr) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
US8648073B2 (en) | 2009-12-30 | 2014-02-11 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
EP2698157A1 (fr) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
WO2014074668A1 (fr) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulateurs de gpr119 et traitement de troubles associés à ceux-ci |
WO2014130608A1 (fr) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Composés bicycliques antidiabétiques |
WO2014139388A1 (fr) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
WO2014151206A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
WO2014151200A2 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
US8853385B2 (en) | 2008-01-17 | 2014-10-07 | Mitsubishi Tanabe Pharma Corporation | Combination therapy comprising SGLT inhibitors and DPP4 inhibitors |
EP2810951A2 (fr) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
WO2014197720A2 (fr) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation |
WO2015051725A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
EP2865670A1 (fr) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
WO2016030534A1 (fr) | 2014-08-29 | 2016-03-03 | Tes Pharma S.R.L. | Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique |
EP2998314A1 (fr) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles |
US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
EP3241839A1 (fr) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
WO2018069532A1 (fr) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique |
WO2018106518A1 (fr) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
WO2018118670A1 (fr) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Composés de spirochromane antidiabétiques |
EP3461819A1 (fr) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibiteurs de la glutaminyl-cyclase |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10654827B2 (en) | 2016-08-19 | 2020-05-19 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2020104456A1 (fr) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique |
US10696657B2 (en) | 2018-02-16 | 2020-06-30 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
WO2020167706A1 (fr) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine |
US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
US10849892B2 (en) | 2017-08-17 | 2020-12-01 | Gilead Sciences, Inc. | Choline salt forms of an HIV capsid inhibitor |
WO2021026047A1 (fr) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
WO2022040070A1 (fr) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de l'orexine de type bicycloheptane pyrrolidine |
US11267799B2 (en) | 2017-08-17 | 2022-03-08 | Gilead Sciences, Inc. | Solid forms of an HIV capsid inhibitor |
EP4000630A1 (fr) | 2014-09-03 | 2022-05-25 | Invex Therapeutics Ltd | Traitement de la pression intracrânienne élevée |
US11680064B2 (en) | 2020-06-25 | 2023-06-20 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
US11787825B2 (en) | 2021-12-03 | 2023-10-17 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
US11807625B2 (en) | 2019-11-26 | 2023-11-07 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
US11944611B2 (en) | 2018-07-16 | 2024-04-02 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
US20030199000A1 (en) * | 2001-08-20 | 2003-10-23 | Valkirs Gunars E. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20030219734A1 (en) * | 2001-04-13 | 2003-11-27 | Biosite Incorporated | Polypeptides related to natriuretic peptides and methods of their identification and use |
US7524635B2 (en) * | 2003-04-17 | 2009-04-28 | Biosite Incorporated | Methods and compositions for measuring natriuretic peptides and uses thereof |
US20040176914A1 (en) * | 2001-04-13 | 2004-09-09 | Biosite Incorporated | Methods and compositions for measuring biologically active natriuretic peptides and for improving their therapeutic potential |
EP1322957B1 (fr) * | 2001-05-04 | 2009-08-12 | Biosite Incorporated | Marqueurs diagnostiques de syndromes coronaires aigus et leurs methodes d'utilisation |
DE60222667T2 (de) * | 2001-06-27 | 2008-07-17 | Smithkline Beecham Corp. | Fluorpyrrolidine als dipeptidylpeptidaseinhibitoren |
US20040219509A1 (en) * | 2001-08-20 | 2004-11-04 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
US20040209307A1 (en) * | 2001-08-20 | 2004-10-21 | Biosite Incorporated | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
EP1419388B1 (fr) * | 2001-08-20 | 2009-10-07 | Biosite Incorporated | Marqueurs diagnostiques d'ictus et de lesions cerebrales et procedes d'utilisation de ces marqueurs |
US7608406B2 (en) * | 2001-08-20 | 2009-10-27 | Biosite, Inc. | Diagnostic markers of stroke and cerebral injury and methods of use thereof |
CA2518465A1 (fr) | 2003-03-25 | 2004-10-14 | Takeda San Diego, Inc. | Inhibiteurs de dipeptidyle peptidase |
JP2006527194A (ja) * | 2003-06-06 | 2006-11-30 | メルク エンド カムパニー インコーポレーテッド | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼ阻害剤としての縮合インドール |
US7678909B1 (en) | 2003-08-13 | 2010-03-16 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CN1867560A (zh) | 2003-08-13 | 2006-11-22 | 武田药品工株式会社 | 4-嘧啶酮衍生物及其作为肽基肽酶抑制剂的用途 |
US7169926B1 (en) | 2003-08-13 | 2007-01-30 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
EP1699777B1 (fr) | 2003-09-08 | 2012-12-12 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidylpeptidase |
AU2004286857A1 (en) * | 2003-11-04 | 2005-05-19 | Merck & Co., Inc. | Fused phenylalanine derivatives as dipeptidyl peptidase-IV inhibitors for the treatment or prevention of diabetes |
NZ548440A (en) * | 2004-02-05 | 2009-07-31 | Kyorin Seiyaku Kk | Bicycloester derivative inhibitng DPP-IV for treatment of diabetes or similar |
KR20060129021A (ko) * | 2004-02-18 | 2006-12-14 | 교린 세이야꾸 가부시키 가이샤 | 비시클로아미드 유도체 |
JP4689599B2 (ja) * | 2004-02-27 | 2011-05-25 | 杏林製薬株式会社 | ビシクロ誘導体 |
US7732446B1 (en) | 2004-03-11 | 2010-06-08 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
UA85871C2 (uk) | 2004-03-15 | 2009-03-10 | Такеда Фармасьютікал Компані Лімітед | Інгібітори дипептидилпептидази |
WO2005118555A1 (fr) | 2004-06-04 | 2005-12-15 | Takeda Pharmaceutical Company Limited | Inhibiteurs de la dipeptidyl peptidase |
WO2006019965A2 (fr) | 2004-07-16 | 2006-02-23 | Takeda San Diego, Inc. | Inhibiteurs de la dipeptidyl peptidase |
US7872124B2 (en) | 2004-12-21 | 2011-01-18 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
CA2599419A1 (fr) | 2005-04-22 | 2006-11-02 | Alantos Pharmaceuticals Holding, Inc. | Inhibiteurs de la dipeptidyl peptidase iv |
US7321055B2 (en) * | 2005-08-04 | 2008-01-22 | Ajinomoto Co., Inc. | Production method of optically active dephenylalanine compounds |
NZ566799A (en) | 2005-09-14 | 2011-04-29 | Takeda Pharmaceutical | Dipeptidyl peptidase inhibitors for treating diabetes |
WO2007102286A1 (fr) * | 2006-03-08 | 2007-09-13 | Kyorin Pharmaceutical Co., Ltd. | Procede de production d'un derive aminoacetylpyrrolidinecarbonitrile et intermediaire utilise pour sa production |
US8324383B2 (en) | 2006-09-13 | 2012-12-04 | Takeda Pharmaceutical Company Limited | Methods of making polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile |
US20080287687A1 (en) | 2006-11-03 | 2008-11-20 | Ajinomoto Co. Inc | Production method of diphenylalanine-Ni (II) complex |
US8093236B2 (en) | 2007-03-13 | 2012-01-10 | Takeda Pharmaceuticals Company Limited | Weekly administration of dipeptidyl peptidase inhibitors |
JPWO2008114857A1 (ja) * | 2007-03-22 | 2010-07-08 | 杏林製薬株式会社 | アミノアセチルピロリジンカルボニトリル誘導体の製造方法 |
EP2146210A1 (fr) | 2008-04-07 | 2010-01-20 | Arena Pharmaceuticals, Inc. | Procédés d'utilisation du récepteur couplé aux protéines A G pour identifier les secrétagogues de peptide YY (PYY) et composés utiles dans le traitement d'états modulés par PYY |
US8476470B2 (en) * | 2008-08-07 | 2013-07-02 | Kyorin Pharmaceutical Co., Ltd. | Process for production of bicyclo[2.2.2]octylamine derivative |
US20110152342A1 (en) * | 2008-08-14 | 2011-06-23 | Hiroshi Uchida | Stabilized pharmaceutical composition |
EP2571855B1 (fr) * | 2010-05-17 | 2014-12-24 | Merck Sharp & Dohme Corp. | Nouveaux inhibiteurs de prolylcarboxypeptidase |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995015309A1 (fr) * | 1993-12-03 | 1995-06-08 | Ferring B.V. | Inhibiteurs de la dp-iv-serine protease |
EP0933379A1 (fr) * | 1996-08-28 | 1999-08-04 | Shionogi & Co., Ltd. | Nouveaux derives de peptides presentant un residu de thiazolyle-alanine |
WO2000056297A2 (fr) * | 1999-03-23 | 2000-09-28 | Ferring B.V. | Compositions favorisant la croissance |
WO2001040180A2 (fr) * | 1999-11-30 | 2001-06-07 | Ferring Bv | Nouveaux agents antidiabetiques |
WO2001081304A1 (fr) * | 2000-04-26 | 2001-11-01 | Ferring Bv | Inhibiteurs de dipeptidyl peptidase iv |
WO2001081337A1 (fr) * | 2000-04-26 | 2001-11-01 | Ferring B.V. | Inhibiteurs de dipeptidyl peptidase iv |
WO2001089569A1 (fr) * | 2000-05-23 | 2001-11-29 | Institut Für Medizintechnologie Magdeburg Gmbh Imtm | Preparations contenant des combinaisons d'inhibiteurs enzymatiques, et leur utilisation |
WO2002053169A2 (fr) * | 2001-01-02 | 2002-07-11 | Keyneurotek Ag I.G. | Utilisation d'inhibiteurs enzymatiques de la dipeptidylpeptidase iv (ec 3.4.14.5) ainsi que de l'aminopeptidase n (ec 3.4.11.2), seuls ou en combinaison, et preparations pharmaceutiques contenant ces inhibiteurs pour la prevention et / ou la therapie de processus et etats pathologiques neurodegeneratifs aigus et chroniques |
EP1245568A1 (fr) * | 2001-03-28 | 2002-10-02 | Les Laboratoires Servier | Dérives sulfonyles d'-aminoacides et leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV ( DPP IV) |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0764151A2 (fr) * | 1994-06-10 | 1997-03-26 | Universitaire Instelling Antwerpen | Purification de proteases serines, et leurs inhibiteurs synthetiques |
US6011155A (en) * | 1996-11-07 | 2000-01-04 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV |
TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
US6803357B1 (en) | 1998-02-02 | 2004-10-12 | New England Medical Center Hospitals, Inc. | Method of regulating glucose metabolism, and reagents related thereto |
DE19823831A1 (de) | 1998-05-28 | 1999-12-02 | Probiodrug Ges Fuer Arzneim | Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen |
CO5150173A1 (es) * | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
GB9906714D0 (en) | 1999-03-23 | 1999-05-19 | Ferring Bv | Compositions for improving fertility |
DE19940130A1 (de) | 1999-08-24 | 2001-03-01 | Probiodrug Ges Fuer Arzneim | Neue Effektoren der Dipeptidyl Peptidase IV zur topischen Anwendung |
EP1228061A4 (fr) | 1999-11-12 | 2004-12-15 | Guilford Pharm Inc | Inhibiteurs de la dipeptidyl peptidase iv; methodes de fabrication et d'utilisation desdits inhibiteurs |
ATE385421T1 (de) | 2000-01-21 | 2008-02-15 | Novartis Pharma Gmbh | Zusammensetzungen bestehend aus dipeptidylpeptidase-iv inhibitoren und antidiabetica |
WO2001062266A2 (fr) | 2000-02-25 | 2001-08-30 | Novo Nordisk A/S | Inhibition de la degenerescence des cellules beta |
US6395767B2 (en) * | 2000-03-10 | 2002-05-28 | Bristol-Myers Squibb Company | Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method |
TW583185B (en) | 2000-06-13 | 2004-04-11 | Novartis Ag | N-(substituted glycyl)-2-cyanopyrrolidines and pharmaceutical composition for inhibiting dipeptidyl peptidase-IV (DPP-IV) or for the prevention or treatment of diseases or conditions associated with elevated levels of DPP-IV comprising the same |
WO2002002560A2 (fr) | 2000-07-04 | 2002-01-10 | Novo Nordisk A/S | Composes heterocycliques inhibiteurs de l'enzyme dpp-iv |
AU2001294196B2 (en) | 2000-10-06 | 2005-11-17 | Tanabe Seiyaku Co., Ltd. | Nitrogenous five-membered ring compounds |
TWI243162B (en) | 2000-11-10 | 2005-11-11 | Taisho Pharmaceutical Co Ltd | Cyanopyrrolidine derivatives |
JP2002265439A (ja) * | 2001-03-08 | 2002-09-18 | Mitsubishi Pharma Corp | シアノピロリジン誘導体およびその医薬用途 |
CA2441092A1 (fr) * | 2001-03-27 | 2002-10-03 | Merck & Co., Inc. | Inhibiteurs de peptidase dipeptidyl destines au traitement ou a la prevention du diabete |
US6573287B2 (en) | 2001-04-12 | 2003-06-03 | Bristo-Myers Squibb Company | 2,1-oxazoline and 1,2-pyrazoline-based inhibitors of dipeptidyl peptidase IV and method |
WO2003000180A2 (fr) | 2001-06-20 | 2003-01-03 | Merck & Co., Inc. | Inhibiteurs de dipeptidyle peptidase pour le traitement du diabete |
GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
GB0125446D0 (en) | 2001-10-23 | 2001-12-12 | Ferring Bv | Novel anti-diabetic agents |
BR0215622A (pt) * | 2002-02-28 | 2004-12-07 | Prosidion Ltd | Inibidores da dpiv com base em glutaminila |
CA2508487A1 (fr) * | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Derives de phenylalanine utilises comme inhibiteurs de la dipeptidylpeptisase pour le traitement ou la prevention de diabetes |
-
2002
- 2002-06-26 JP JP2003508713A patent/JP4300108B2/ja not_active Expired - Fee Related
- 2002-06-26 ES ES02746739T patent/ES2296962T3/es not_active Expired - Lifetime
- 2002-06-26 WO PCT/US2002/020466 patent/WO2003002530A2/fr active IP Right Grant
- 2002-06-26 AU AU2002316437A patent/AU2002316437A1/en not_active Abandoned
- 2002-06-26 AT AT02746739T patent/ATE380175T1/de not_active IP Right Cessation
- 2002-06-26 DE DE60223920T patent/DE60223920T2/de not_active Expired - Lifetime
- 2002-06-26 EP EP02746739A patent/EP1399420B1/fr not_active Expired - Lifetime
- 2002-06-26 US US10/481,288 patent/US7196201B2/en not_active Expired - Fee Related
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995015309A1 (fr) * | 1993-12-03 | 1995-06-08 | Ferring B.V. | Inhibiteurs de la dp-iv-serine protease |
EP0933379A1 (fr) * | 1996-08-28 | 1999-08-04 | Shionogi & Co., Ltd. | Nouveaux derives de peptides presentant un residu de thiazolyle-alanine |
WO2000056297A2 (fr) * | 1999-03-23 | 2000-09-28 | Ferring B.V. | Compositions favorisant la croissance |
WO2001040180A2 (fr) * | 1999-11-30 | 2001-06-07 | Ferring Bv | Nouveaux agents antidiabetiques |
WO2001081304A1 (fr) * | 2000-04-26 | 2001-11-01 | Ferring Bv | Inhibiteurs de dipeptidyl peptidase iv |
WO2001081337A1 (fr) * | 2000-04-26 | 2001-11-01 | Ferring B.V. | Inhibiteurs de dipeptidyl peptidase iv |
WO2001089569A1 (fr) * | 2000-05-23 | 2001-11-29 | Institut Für Medizintechnologie Magdeburg Gmbh Imtm | Preparations contenant des combinaisons d'inhibiteurs enzymatiques, et leur utilisation |
WO2002053169A2 (fr) * | 2001-01-02 | 2002-07-11 | Keyneurotek Ag I.G. | Utilisation d'inhibiteurs enzymatiques de la dipeptidylpeptidase iv (ec 3.4.14.5) ainsi que de l'aminopeptidase n (ec 3.4.11.2), seuls ou en combinaison, et preparations pharmaceutiques contenant ces inhibiteurs pour la prevention et / ou la therapie de processus et etats pathologiques neurodegeneratifs aigus et chroniques |
EP1245568A1 (fr) * | 2001-03-28 | 2002-10-02 | Les Laboratoires Servier | Dérives sulfonyles d'-aminoacides et leur utilisation en tant qu'inhibiteurs de dipeptidyl-peptidase IV ( DPP IV) |
Non-Patent Citations (7)
Title |
---|
ASHWORTH D M ET AL: "4-Cyanothiazolidides as very potent, stable inhibitors of dipeptidyl peptidase IV" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 6, no. 22, 19 November 1996 (1996-11-19), pages 2745-2748, XP004135888 ISSN: 0960-894X * |
AUGUSTYNS K ET AL: "THE UNIQUE PROPERTIES OF DIPEPTIDYL-PEPTIDASE IV (DPP IV/CD26) AND THE THERAPEUTIC POTENTIAL OF DPP IV INHIBITORS" CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS BV, BE, vol. 6, no. 4, 1999, pages 311-327, XP000870290 ISSN: 0929-8673 * |
DATABASE CAPLUS [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KITASHIMA, HIROSHI ET AL: "Preparation of N-(.alpha.-aminoacyl)-2-cyanopyrrolidine derivatives as inhibitors of dipeptidyl peptidase IV (DPP-IV) for drugs" retrieved from STN Database accession no. 137:232910 XP002224329 -& JP 2002 265439 A (MITSUBISHI WELL PHARMA K. K., JAPAN) 18 September 2002 (2002-09-18) * |
JIANG J D ET AL: "Inhibition of uman immunodeficiency virus type 1 infection in a T-cell line (CEM) by new dipeptidyl-peptidase IV (CD26) inhibitors" RESEARCH IN VIROLOGY, ELSEVIER, PARIS, FR, vol. 4, no. 148, 1 July 1997 (1997-07-01), pages 255-266, XP002074032 ISSN: 0923-2516 * |
LI J ET AL: "AMINOACYLPYRROLIDINE-2-NITRILES: POTENT AND STABLE INHIBITORS OF DEIPEPTIDYL-PEPTIDASE 4 (CD 26)" ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, NEW YORK, US, US, vol. 323, no. 1, October 1995 (1995-10), pages 148-154, XP000965067 ISSN: 0003-9861 * |
LOREY S ET AL: "NEW FLUOROGENIC DIPEPTIDYL PEPTIDASE IV/CD26 SUBSTRATES AND INHIBITORS" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 421, 1997, pages 157-160, XP001008342 ISSN: 0065-2598 * |
STOECKEL-MASCHEK A ET AL: "POTENT INHIBITORS OF DIPEPTIDYL PEPTIDASE IV AND THEIR MECHANISMS OF INHIBITION" ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, SPRING ST., NY, US, vol. 477, 2000, pages 117-123, XP008000943 ISSN: 0065-2598 * |
Cited By (153)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7026316B2 (en) | 2001-03-27 | 2006-04-11 | Merck & Co., Inc. | Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004002986A2 (fr) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Nouveaux dérivés de benzimidazole |
WO2004050022A2 (fr) * | 2002-12-04 | 2004-06-17 | Merck & Co., Inc. | Derives de phenylalanine utilises comme inhibiteurs de la dipeptidylpeptisase pour le traitement ou la prevention de diabetes |
WO2004050022A3 (fr) * | 2002-12-04 | 2004-08-05 | Merck & Co Inc | Derives de phenylalanine utilises comme inhibiteurs de la dipeptidylpeptisase pour le traitement ou la prevention de diabetes |
JP2006510630A (ja) * | 2002-12-04 | 2006-03-30 | メルク エンド カムパニー インコーポレーテッド | 糖尿病を治療又は予防するためのジペプチジルペプチダーゼ阻害剤としてのフェニルアラニン誘導体 |
US7309714B2 (en) | 2002-12-04 | 2007-12-18 | Merck & Co., Inc. | Phenylalanine derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
EP2206496A1 (fr) | 2003-05-05 | 2010-07-14 | Probiodrug AG | Utilisation médicale d'inhibiteurs de glutaminyl- et de glutamate cyclases |
WO2004098625A2 (fr) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Utilisation d'effecteurs de glutaminyl- et de glutamate-cyclases |
WO2004098591A2 (fr) | 2003-05-05 | 2004-11-18 | Probiodrug Ag | Inhibiteurs de glutaminyl-cyclase |
DE202004021723U1 (de) | 2003-05-05 | 2010-07-15 | Probiodrug Ag | Medizinische Verwendung von Hemmern von Glutaminyl- und Glutamatcyclasen |
US7560455B2 (en) | 2003-05-14 | 2009-07-14 | Merck & Co., Inc. | 3-Amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
WO2004104215A3 (fr) * | 2003-05-21 | 2005-06-09 | Bayer Healthcare Ag | Approches diagnostiques et therapeutiques des maladies associees a la dipeptidylpeptidase 7 (dpp7) |
WO2004104215A2 (fr) * | 2003-05-21 | 2004-12-02 | Bayer Healthcare Ag | Approches diagnostiques et therapeutiques des maladies associees a la dipeptidylpeptidase 7 (dpp7) |
US6995183B2 (en) | 2003-08-01 | 2006-02-07 | Bristol Myers Squibb Company | Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods |
EP1997489A1 (fr) | 2003-08-01 | 2008-12-03 | Bristol-Myers Squibb Company | Derivés de l'adamantylglycine en tant que inhibiteurs de la dipeptidyl peptidase IV pour le traitement de la diabetes |
WO2005028438A1 (fr) | 2003-09-22 | 2005-03-31 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de piperidine |
WO2005033099A3 (fr) * | 2003-10-03 | 2005-06-30 | Glenmark Pharmaceuticals Ltd | Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant |
WO2005033099A2 (fr) * | 2003-10-03 | 2005-04-14 | Glenmark Pharmaceuticals Ltd. | Nouveaux inhibiteurs de dipeptidylpeptidase iv, leurs procedes de preparation et compositions les contenant |
EP2289498A1 (fr) | 2003-10-15 | 2011-03-02 | Probiodrug AG | Utilisation des inhibiteurs de la glutaminyl cyclase |
WO2005049027A2 (fr) | 2003-11-03 | 2005-06-02 | Probiodrug Ag | Combinaisons utiles au traitement de troubles neuronaux |
EP2338490A2 (fr) | 2003-11-03 | 2011-06-29 | Probiodrug AG | Combinaisons utiles pour le traitement de désordres neuronales |
JP2014159436A (ja) * | 2003-11-17 | 2014-09-04 | Novartis Ag | ジペプチジルペプチダーゼiv阻害剤の使用 |
JP2018039816A (ja) * | 2003-11-17 | 2018-03-15 | ノバルティス アーゲー | ジペプチジルペプチダーゼiv阻害剤の使用 |
JP2012211146A (ja) * | 2003-11-17 | 2012-11-01 | Novartis Ag | ジペプチジルペプチダーゼiv阻害剤の使用 |
WO2005049022A3 (fr) * | 2003-11-17 | 2005-07-21 | Novartis Ag | Utilisation de composes organiques |
JP2007511487A (ja) * | 2003-11-17 | 2007-05-10 | ノバルティス アクチエンゲゼルシャフト | ジペプチジルペプチダーゼiv阻害剤の使用 |
WO2005049022A2 (fr) * | 2003-11-17 | 2005-06-02 | Novartis Ag | Utilisation de composes organiques |
EP2839832A3 (fr) * | 2003-11-17 | 2015-06-24 | Novartis AG | Utilisation d'inhibiteurs de la dipeptidyl peptidase IV |
WO2005075436A2 (fr) | 2004-02-05 | 2005-08-18 | Probiodrug Ag | Nouveaux inhibiteurs de la glutaminyl-cyclase |
US7897633B2 (en) | 2004-02-05 | 2011-03-01 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
EP2088154A1 (fr) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Procédés et compositions pour le traitement de troubles gastro-intestinaux |
WO2005097759A1 (fr) | 2004-03-29 | 2005-10-20 | Merck & Co., Inc. | Utilisation de diaryltriazoles comme inhibiteurs de la 11-beta-hydroxysteroide deshydrogenase-1 |
EP2305352A1 (fr) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | Inhibiteurs de la 5-alpha-reductase pour le traitement d'hommes aux troubles métaboliques et anthropométriques |
US7842707B2 (en) | 2004-07-23 | 2010-11-30 | Nuada, Llc | Peptidase inhibitors |
WO2006017542A1 (fr) | 2004-08-06 | 2006-02-16 | Merck & Co., Inc. | Composés de sulfonyle comme inhibiteurs de la 11-béta-hydroxystéroide déshydrogénase-1 |
EP2116235A1 (fr) | 2005-01-10 | 2009-11-11 | Arena Pharmaceuticals, Inc. | Thérapie combinée pour le traitement des diabètes et des conditions associées, et pour le traitement des conditions améliorées par l'augmentation du niveau de sang GLP-1 |
WO2006129826A1 (fr) | 2005-05-30 | 2006-12-07 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de piperidine |
EP2191824A1 (fr) | 2005-06-10 | 2010-06-02 | Novartis AG | Formulation de 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile à libération modifiée |
WO2007018248A1 (fr) | 2005-08-10 | 2007-02-15 | Banyu Pharmaceutical Co., Ltd. | Composé de pyridone |
WO2007024004A1 (fr) | 2005-08-24 | 2007-03-01 | Banyu Pharmaceutical Co., Ltd. | Dérivé phénylpyridone |
WO2007029847A1 (fr) | 2005-09-07 | 2007-03-15 | Banyu Pharmaceutical Co., Ltd. | Dérivé de pyridone substitué aromatique bicylique |
US8222411B2 (en) | 2005-09-16 | 2012-07-17 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2007041052A2 (fr) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Derives spiropiperidines acyles convenant comme modulateurs des recepteurs de la melanocortine-4 |
WO2007049798A1 (fr) | 2005-10-27 | 2007-05-03 | Banyu Pharmaceutical Co., Ltd. | Nouveau derive de benzoxathiine |
WO2007055418A1 (fr) | 2005-11-10 | 2007-05-18 | Banyu Pharmaceutical Co., Ltd. | Derive spiro aza-substitue |
EP1801098A1 (fr) | 2005-12-16 | 2007-06-27 | Merck Sante | Dérivés de 2-Adamantylurea comme inhibiteurs de 11B-HSD1 |
WO2007072083A1 (fr) | 2005-12-23 | 2007-06-28 | Prosidion Limited | Traitement du diabete de type 2 par combinaison d'un inhibiteur de dpiv a de la metformine ou de la thiazolidinedione |
US7960384B2 (en) | 2006-03-28 | 2011-06-14 | Takeda Pharmaceutical Company Limited | Dipeptidyl peptidase inhibitors |
WO2007120702A2 (fr) | 2006-04-11 | 2007-10-25 | Arena Pharmaceuticals, Inc. | Agonistes du récepteur de gpr119 dans des procédés d'augmentation de la masse osseuse et de traitement de l'ostéoporose et autres états se caractérisant par une masse osseuse faible, et thérapie de combinaison associée |
EP2253311A2 (fr) | 2006-04-11 | 2010-11-24 | Arena Pharmaceuticals, Inc. | Utilisation d'agonistes du récepteur de GPR119 dans des procédés d'augmentation de la masse osseuse et de traitement de l'ostéoporose, et thérapie de combinaison associée |
US7728146B2 (en) | 2006-04-12 | 2010-06-01 | Probiodrug Ag | Enzyme inhibitors |
EP2946778A1 (fr) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de la synthèse d'acides gras |
EP2698157A1 (fr) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras |
WO2008038692A1 (fr) | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | dÉrivÉ de diarylcÉtimine |
WO2008055945A1 (fr) | 2006-11-09 | 2008-05-15 | Probiodrug Ag | Dérivés 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one utiles en tant qu' inhibiteurs de la glutaminyl-cyclase dans le traitement des ulcères, du cancer et d'autres maladies |
US8084605B2 (en) | 2006-11-29 | 2011-12-27 | Kelly Ron C | Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor |
WO2008065141A1 (fr) | 2006-11-30 | 2008-06-05 | Probiodrug Ag | Nouveaux inhibiteurs de glutaminylcyclase |
WO2008074384A1 (fr) | 2006-12-21 | 2008-06-26 | Merck Patent Gmbh | Dérivés de 2-adamantyle-butyramide en tant qu'inhibiteurs sélectifs de 11βêta-hsd1 |
WO2008120653A1 (fr) | 2007-04-02 | 2008-10-09 | Banyu Pharmaceutical Co., Ltd. | Dérivé d'indoledione |
WO2008120813A1 (fr) | 2007-04-03 | 2008-10-09 | Mitsubishi Tanabe Pharma Corporation | Utilisation combinée de composé inhibiteur de dipeptidylpeptidase iv, et d'adoucisseur |
EP2865670A1 (fr) | 2007-04-18 | 2015-04-29 | Probiodrug AG | Dérivés de thio-urée utilisés comme inhibiteurs de la glutaminyl cyclase |
WO2008137105A1 (fr) | 2007-05-07 | 2008-11-13 | Merck & Co., Inc. | Procédé de traitement à l'aide de composés aromatiques fusionnés ayant une activité anti-diabétique |
EP2998314A1 (fr) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonistes de guanylase cyclase utiles pour le traitement de troubles gastro-intestinaux, d'inflammation, de cancer et d'autres troubles |
US8853385B2 (en) | 2008-01-17 | 2014-10-07 | Mitsubishi Tanabe Pharma Corporation | Combination therapy comprising SGLT inhibitors and DPP4 inhibitors |
WO2009110510A1 (fr) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | Dérivé d'alkylaminopyridine |
WO2009119726A1 (fr) | 2008-03-28 | 2009-10-01 | 萬有製薬株式会社 | Dérivé de diarylméthylamide à activité antagoniste sur un récepteur d'hormone concentrant la mélanine |
WO2009127321A1 (fr) | 2008-04-18 | 2009-10-22 | Merck Patent Gmbh, | Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs de fxr |
EP2110374A1 (fr) | 2008-04-18 | 2009-10-21 | Merck Sante | Dérivés de benzofurane, benzothiophène, benzothiazol en tant que modulateurs FXR |
EP2810951A2 (fr) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles |
WO2009154132A1 (fr) | 2008-06-19 | 2009-12-23 | 萬有製薬株式会社 | Dérivé de spirodiamine-diarylcétoxime |
EP3241839A1 (fr) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utiles pour le traitement de troubles gastro-intestinaux, inflammatoires, cancéreux et autres |
WO2010013595A1 (fr) | 2008-07-30 | 2010-02-04 | 萬有製薬株式会社 | Dérivé de cycloalkylamine à noyaux fusionnés à (5 chaînons)-(5 chaînons) ou (5 chaînons)–(6 chaînons) |
WO2010047982A1 (fr) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Nouveaux dérivés de benzimidazole cycliques utiles comme agents anti-diabétiques |
WO2010051236A1 (fr) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Antagonistes d'isonicotinamide des récepteurs de l'orexine |
WO2010051206A1 (fr) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Nouveaux agents antidiabétiques utiles avec des dérivés de benzimidazole cycliques |
WO2010056717A1 (fr) | 2008-11-17 | 2010-05-20 | Merck Sharp & Dohme Corp. | Amines bicycliques substituées pour le traitement du diabète |
WO2011005929A1 (fr) | 2009-07-09 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Dérivé de pipéridine et son utilisation pour le traitement du diabète et de l'obésité |
WO2011011508A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés doxazépine benzofusionnés en tant quinhibiteurs de la coenzyme-stéaroyle a delta-9 désaturase |
WO2011011506A1 (fr) | 2009-07-23 | 2011-01-27 | Schering Corporation | Composés oxazépine spirocyclique en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase |
WO2011029920A1 (fr) | 2009-09-11 | 2011-03-17 | Probiodrug Ag | Dérivés hétérocycliques en tant qu'inhibiteurs de glutaminyle cyclase |
WO2011058193A1 (fr) | 2009-11-16 | 2011-05-19 | Mellitech | Dérivés de [1,5]-diazocine |
US8765728B2 (en) | 2009-11-16 | 2014-07-01 | Mellitech | [1,5]-diazocin derivatives |
EP2923706A1 (fr) | 2009-12-03 | 2015-09-30 | Synergy Pharmaceuticals Inc. | Agonistes de guanylate cyclase utiles pour le traitement de l'hypercholestérolémie |
WO2011069038A2 (fr) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonistes de la guanylate cyclase utiles dans le traitement de l'hypercholestérolémie, de l'athérosclérose, d'une coronaropathie, des calculs biliaires, de l'obésité et d'autres maladies cardiovasculaires |
US9340523B2 (en) | 2009-12-30 | 2016-05-17 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
US8648073B2 (en) | 2009-12-30 | 2014-02-11 | Fochon Pharma, Inc. | Certain dipeptidyl peptidase inhibitors |
WO2011106273A1 (fr) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Nouveaux dérivés benzimidazole cycliques utiles comme agents antidiabétiques |
WO2011107530A2 (fr) | 2010-03-03 | 2011-09-09 | Probiodrug Ag | Nouveaux inhibiteurs |
WO2011110613A1 (fr) | 2010-03-10 | 2011-09-15 | Probiodrug Ag | Inhibiteurs hétérocycliques de la glutaminyl cyclase (qc, ec 2.3.2.5) |
WO2011127051A1 (fr) | 2010-04-06 | 2011-10-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur de gpr119 et traitement de troubles associés |
WO2011131748A2 (fr) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Nouveaux inhibiteurs |
WO2012027331A1 (fr) | 2010-08-27 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés |
EP3323818A1 (fr) | 2010-09-22 | 2018-05-23 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés |
WO2012040279A1 (fr) | 2010-09-22 | 2012-03-29 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement des troubles qui lui sont liés |
EP3243385A1 (fr) | 2011-02-25 | 2017-11-15 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques |
WO2012116145A1 (fr) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'azabenzimidazole cyclique utiles en tant qu'agents antidiabétiques |
WO2012118972A2 (fr) | 2011-03-01 | 2012-09-07 | Synegy Pharmaceuticals Inc. | Procédé de préparation d'agonistes du guanylate cyclase c |
WO2012123563A1 (fr) | 2011-03-16 | 2012-09-20 | Probiodrug Ag | Dérivés de benzimidazole en tant qu'inhibiteurs de la glutaminyl cyclase |
WO2012135570A1 (fr) | 2011-04-01 | 2012-10-04 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles qui lui sont associés |
WO2012145361A1 (fr) | 2011-04-19 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012145603A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012145604A1 (fr) | 2011-04-22 | 2012-10-26 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles liés à celui-ci |
WO2012170702A1 (fr) | 2011-06-08 | 2012-12-13 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés à celui-ci |
US9540343B2 (en) | 2011-07-06 | 2017-01-10 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
US11034668B2 (en) | 2011-07-06 | 2021-06-15 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
US10370358B2 (en) | 2011-07-06 | 2019-08-06 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
US9944619B2 (en) | 2011-07-06 | 2018-04-17 | Gilead Sciences, Inc. | Compounds for the treatment of HIV |
WO2013055910A1 (fr) | 2011-10-12 | 2013-04-18 | Arena Pharmaceuticals, Inc. | Modulateurs du récepteur gpr119 et traitement de troubles associés |
WO2013059222A1 (fr) | 2011-10-19 | 2013-04-25 | Merck Sharp & Dohme Corp. | Antagonistes des récepteurs de l'orexine à base de 2-pyrydyloxy-4-nitrile |
EP3708179A1 (fr) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations d'agonistes de guanylate cyclase c et leurs procédés d'utilisation |
EP4309673A2 (fr) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations d'agonistes de guanylate cyclase c et leurs procédés d'utilisation |
WO2013138352A1 (fr) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations d'agonistes de la guanylate cyclase c et procédés d'utilisation |
WO2014022528A1 (fr) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
WO2014074668A1 (fr) | 2012-11-08 | 2014-05-15 | Arena Pharmaceuticals, Inc. | Modulateurs de gpr119 et traitement de troubles associés à ceux-ci |
WO2014130608A1 (fr) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Composés bicycliques antidiabétiques |
WO2014139388A1 (fr) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Nouveaux dérivés d'indole utiles en tant qu'agents antidiabétiques |
WO2014151200A2 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions utiles pour le traitement de troubles gastro-intestinaux |
WO2014151206A1 (fr) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonistes de la guanylate cyclase et leurs utilisations |
WO2014197720A2 (fr) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Agonistes ultra-purs de guanylate cyclase c, leur procédé de production et d'utilisation |
WO2015051725A1 (fr) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Composés tricycliques antidiabétiques |
WO2016030534A1 (fr) | 2014-08-29 | 2016-03-03 | Tes Pharma S.R.L. | Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique |
US11254644B2 (en) | 2014-08-29 | 2022-02-22 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
US9708272B2 (en) | 2014-08-29 | 2017-07-18 | Tes Pharma S.R.L. | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase |
US10513499B2 (en) | 2014-08-29 | 2019-12-24 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
EP4000630A1 (fr) | 2014-09-03 | 2022-05-25 | Invex Therapeutics Ltd | Traitement de la pression intracrânienne élevée |
US10555929B2 (en) | 2015-03-09 | 2020-02-11 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10772865B2 (en) | 2015-03-09 | 2020-09-15 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US11400072B2 (en) | 2015-03-09 | 2022-08-02 | Coherus Biosciences, Inc. | Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy |
US10654827B2 (en) | 2016-08-19 | 2020-05-19 | Gilead Sciences, Inc. | Therapeutic compounds |
US11993583B2 (en) | 2016-08-19 | 2024-05-28 | Gilead Sciences, Inc. | Therapeutic compounds |
WO2018069532A1 (fr) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique |
WO2018106518A1 (fr) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Composés hétérocycliques antidiabétiques |
WO2018118670A1 (fr) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Composés de spirochromane antidiabétiques |
US11253508B2 (en) | 2017-04-03 | 2022-02-22 | Coherus Biosciences, Inc. | PPARy agonist for treatment of progressive supranuclear palsy |
US10849892B2 (en) | 2017-08-17 | 2020-12-01 | Gilead Sciences, Inc. | Choline salt forms of an HIV capsid inhibitor |
US11833143B2 (en) | 2017-08-17 | 2023-12-05 | Gilead Sciences, Inc. | Choline salt forms of an HIV capsid inhibitor |
US11267799B2 (en) | 2017-08-17 | 2022-03-08 | Gilead Sciences, Inc. | Solid forms of an HIV capsid inhibitor |
US11266638B2 (en) | 2017-08-17 | 2022-03-08 | Gilead Sciences, Inc. | Choline salt forms of an HIV capsid inhibitor |
EP3461819A1 (fr) | 2017-09-29 | 2019-04-03 | Probiodrug AG | Inhibiteurs de la glutaminyl-cyclase |
US11267801B2 (en) | 2018-02-15 | 2022-03-08 | Gilead Sciences, Inc. | Therapeutic compounds |
US10836746B2 (en) | 2018-02-15 | 2020-11-17 | Gilead Sciences, Inc. | Therapeutic compounds |
US11753399B2 (en) | 2018-02-15 | 2023-09-12 | Gilead Sciences, Inc. | Therapeutic compounds |
US11760746B2 (en) | 2018-02-16 | 2023-09-19 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
US11117886B2 (en) | 2018-02-16 | 2021-09-14 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
US10696657B2 (en) | 2018-02-16 | 2020-06-30 | Gilead Sciences, Inc. | Methods and intermediates for preparing therapeutic compounds |
US11944611B2 (en) | 2018-07-16 | 2024-04-02 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
WO2020104456A1 (fr) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | Inhibiteurs de la semialdéhyde décarboxylase de l'acide alpha-amino-bêta-carboxymuconique |
WO2020167706A1 (fr) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de l'orexine 5-alkyl-pyrrolidine |
WO2021026047A1 (fr) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de l'orexine de type pyrrolidine et pipéridine hétéroaryle |
US11807625B2 (en) | 2019-11-26 | 2023-11-07 | Gilead Sciences, Inc. | Capsid inhibitors for the prevention of HIV |
US11680064B2 (en) | 2020-06-25 | 2023-06-20 | Gilead Sciences, Inc. | Capsid inhibitors for the treatment of HIV |
WO2022040070A1 (fr) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Agonistes du récepteur de l'orexine de type bicycloheptane pyrrolidine |
US11787825B2 (en) | 2021-12-03 | 2023-10-17 | Gilead Sciences, Inc. | Therapeutic compounds for HIV virus infection |
Also Published As
Publication number | Publication date |
---|---|
JP2005518337A (ja) | 2005-06-23 |
ES2296962T3 (es) | 2008-05-01 |
DE60223920D1 (en) | 2008-01-17 |
US20040167341A1 (en) | 2004-08-26 |
EP1399420B1 (fr) | 2007-12-05 |
JP4300108B2 (ja) | 2009-07-22 |
AU2002316437A1 (en) | 2003-03-03 |
ATE380175T1 (de) | 2007-12-15 |
DE60223920T2 (de) | 2008-11-13 |
US7196201B2 (en) | 2007-03-27 |
EP1399420A2 (fr) | 2004-03-24 |
WO2003002530A3 (fr) | 2003-04-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7196201B2 (en) | Pyrrolidines as dipeptidyl peptidase inhibitors | |
EP1399433B1 (fr) | Fluoropyrrolidines inhibitrices de la dipeptidyl peptidase | |
US7132443B2 (en) | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | |
AU2002322344A1 (en) | Fluoropyrrolidines as dipeptidyl peptidase inhibitors | |
US10538537B2 (en) | Inhibitors of arginase and their therapeutic applications | |
ES2291966T3 (es) | Inhibidores de dpp-iv. | |
KR100848491B1 (ko) | 베타아미노기를 갖는 2-싸이아졸리딘 유도체, 이의약학적으로 허용 가능한 염 및 이의 제조 방법 | |
WO2005058849A1 (fr) | Nouveaux inhibiteurs de dipeptidyle peptidase iv, leur procede de preparation et compositions les contenant | |
CA2450579A1 (fr) | Inhibiteurs de dipeptidyle peptidase pour le traitement du diabete | |
WO2006090244A1 (fr) | Nouveaux derives d'adamantine utilises en tant qu'inhibiteurs de dipeptidyl peptidase iv, procedes de preparation associes, et compositions pharmaceutiques les contenant | |
US20050192324A1 (en) | Novel dipeptidyl peptidase IV inhibitors; processes for their preparation and compositions thereof | |
ZA200309170B (en) | Fluoropyrrolidines as dipeptidyl peptidase inhibitors. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 10481288 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003508713 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002746739 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002746739 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2004111664 Country of ref document: RU Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 2004111793 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002746739 Country of ref document: EP |